NYSE: CRL
Charles River Laboratories
Health Care · Services-Commercial Physical & Biological Research
52-week range
$146.20$379.63
Stock price
Market cap
At each fiscal year end, then the latest quarter end: closing price × shares outstanding.Figures shown are for the trailing 12 months to Jun 27, 2026. Hover or tap a column for another year.$10.3B
Show tableHide table
| Period | Market cap |
|---|---|
| FY2016, ended Dec 31, 2016 | $3.61B |
| FY2017, ended Dec 30, 2017 | $5.19B |
| FY2018, ended Dec 29, 2018 | $5.39B |
| FY2019, ended Dec 28, 2019 | $7.44B |
| FY2020, ended Dec 26, 2020 | $12.5B |
| FY2021, ended Dec 25, 2021 | $18.6B |
| FY2022, ended Dec 31, 2022 | $11.1B |
| FY2023, ended Dec 30, 2023 | $12.1B |
| FY2024, ended Dec 28, 2024 | $9.52B |
| FY2025, ended Dec 27, 2025 | $10.0B |
| Trailing 12 months to Jun 27, 2026 (through Q2 FY2026) | $10.3B |
Revenue
By fiscal year, then the trailing 12 months.Figures shown are for the trailing 12 months to Jun 27, 2026. Hover or tap a column for another year.$4.00B
Show tableHide table
| Period | Revenue |
|---|---|
| FY2016, ended Dec 31, 2016 | $1.68B |
| FY2017, ended Dec 30, 2017 | $1.86B |
| FY2018, ended Dec 29, 2018 | $2.27B |
| FY2019, ended Dec 28, 2019 | $2.62B |
| FY2020, ended Dec 26, 2020 | $2.92B |
| FY2021, ended Dec 25, 2021 | $3.54B |
| FY2022, ended Dec 31, 2022 | $3.98B |
| FY2023, ended Dec 30, 2023 | $4.13B |
| FY2024, ended Dec 28, 2024 | $4.05B |
| FY2025, ended Dec 27, 2025 | $4.02B |
| Trailing 12 months to Jun 27, 2026 (through Q2 FY2026) | $4.00B |
Net income and free cash flow
By fiscal year, then the trailing 12 months. Free cash flow is operating cash flow minus capex.Figures shown are for the trailing 12 months to Jun 27, 2026. Hover or tap a column for another year.Show tableHide table
| Period | Net income | Free cash flow |
|---|---|---|
| FY2016, ended Dec 31, 2016 | $155M | $262M |
| FY2017, ended Dec 30, 2017 | $123M | $236M |
| FY2018, ended Dec 29, 2018 | $226M | $301M |
| FY2019, ended Dec 28, 2019 | $252M | $340M |
| FY2020, ended Dec 26, 2020 | $364M | $380M |
| FY2021, ended Dec 25, 2021 | $391M | $532M |
| FY2022, ended Dec 31, 2022 | $486M | $295M |
| FY2023, ended Dec 30, 2023 | $475M | $365M |
| FY2024, ended Dec 28, 2024 | $22.2M | $502M |
| FY2025, ended Dec 27, 2025 | −$144M | $518M |
| Trailing 12 months to Jun 27, 2026 (through Q2 FY2026) | −$238M | $371M |
Cash and cash equivalents
At each fiscal year end, then the latest quarter end.Figures shown are for the trailing 12 months to Jun 27, 2026. Hover or tap a column for another year.$192M
Show tableHide table
| Period | Cash and cash equivalents |
|---|---|
| FY2016, ended Dec 31, 2016 | $118M |
| FY2017, ended Dec 30, 2017 | $164M |
| FY2018, ended Dec 29, 2018 | $195M |
| FY2019, ended Dec 28, 2019 | $238M |
| FY2020, ended Dec 26, 2020 | $228M |
| FY2021, ended Dec 25, 2021 | $241M |
| FY2022, ended Dec 31, 2022 | $234M |
| FY2023, ended Dec 30, 2023 | $277M |
| FY2024, ended Dec 28, 2024 | $195M |
| FY2025, ended Dec 27, 2025 | $214M |
| Trailing 12 months to Jun 27, 2026 (through Q2 FY2026) | $192M |
Total debt
At each fiscal year end, then the latest quarter end. Short- and long-term borrowings, excluding leases.Figures shown are for the trailing 12 months to Jun 27, 2026. Hover or tap a column for another year.$2.63B
Show tableHide table
| Period | Total debt |
|---|---|
| FY2016, ended Dec 31, 2016 | $1.18B |
| FY2017, ended Dec 30, 2017 | $1.09B |
| FY2018, ended Dec 29, 2018 | $1.61B |
| FY2019, ended Dec 28, 2019 | $1.89B |
| FY2020, ended Dec 26, 2020 | $1.98B |
| FY2021, ended Dec 25, 2021 | $2.66B |
| FY2022, ended Dec 31, 2022 | $2.71B |
| FY2023, ended Dec 30, 2023 | $2.65B |
| FY2024, ended Dec 28, 2024 | $2.24B |
| FY2025, ended Dec 27, 2025 | $2.14B |
| Trailing 12 months to Jun 27, 2026 (through Q2 FY2026) | $2.63B |
Shares outstanding
At each fiscal year end, then the latest quarter end, adjusted for splits. Up 0.8% since 2016.Figures shown are for the trailing 12 months to Jun 27, 2026. Hover or tap a column for another year.47.7M
Show tableHide table
| Period | Shares outstanding |
|---|---|
| FY2016, ended Dec 31, 2016 | 47.4M |
| FY2017, ended Dec 30, 2017 | 47.4M |
| FY2018, ended Dec 29, 2018 | 48.2M |
| FY2019, ended Dec 28, 2019 | 49.0M |
| FY2020, ended Dec 26, 2020 | 49.8M |
| FY2021, ended Dec 25, 2021 | 50.5M |
| FY2022, ended Dec 31, 2022 | 51.0M |
| FY2023, ended Dec 30, 2023 | 51.3M |
| FY2024, ended Dec 28, 2024 | 51.1M |
| FY2025, ended Dec 27, 2025 | 49.2M |
| Trailing 12 months to Jun 27, 2026 (through Q2 FY2026) | 47.7M |
Buybacks and new shares
By fiscal year, then the trailing 12 months, in dollars. Below zero: bought back. Above zero: issued to employees, sold or used in acquisitions.Figures shown are for the trailing 12 months to Jun 27, 2026. Hover or tap a column for another year.Net: $241M more bought back than issued
Show tableHide table
| Period | Bought back | Paid to employees |
|---|---|---|
| FY2016, ended Dec 31, 2016 | $12.3M | $43.6M |
| FY2017, ended Dec 30, 2017 | $107M | $44.0M |
| FY2018, ended Dec 29, 2018 | $13.8M | $47.3M |
| FY2019, ended Dec 28, 2019 | $18.1M | $57.3M |
| FY2020, ended Dec 26, 2020 | $24.0M | $56.3M |
| FY2021, ended Dec 25, 2021 | $40.7M | $71.5M |
| FY2022, ended Dec 31, 2022 | $38.7M | $73.6M |
| FY2023, ended Dec 30, 2023 | $24.2M | $72.0M |
| FY2024, ended Dec 28, 2024 | $119M | $69.9M |
| FY2025, ended Dec 27, 2025 | $361M | $71.1M |
| Trailing 12 months to Jun 27, 2026 (through Q2 FY2026) | $324M | $83.1M |
Revenue (TTM)
$4.00B
−0.7% YoY
Net income (TTM)
−$238M
n/m YoY
Cash
$192M
+5.0% YoY
Total debt
$2.63B
+12.6% YoY
Valuation
At current price- Market Cap
- $17.2B
- P/E
- n/m. Market cap / net income (TTM)
- Forward P/E
- —. Needs analyst estimates; not available from the current data provider
- Price / Sales
- 4.3×
- Price / Book
- 6.0×
- EV / EBITDA
- 50.5×
Growth
Trailing 12 months- Revenue (TTM)
- $4.00B
- Revenue Growth YoY
- −0.7%
- Revenue CAGR 3Y
- 0.3%
- Revenue CAGR 5Y
- 6.5%
- EPS Growth YoY
- n/m. Diluted EPS, TTM vs. TTM a year earlier
- Net Income Growth YoY
- n/m. TTM vs. TTM a year earlier
Profitability
Trailing 12 months- Gross Margin
- —
- Operating Margin
- 2.3%
- Net Margin
- −6.0%
- FCF Margin
- 9.3%
- Return on Equity
- −7.7%
Earnings
Trailing 12 months- Net Income
- −$238M
- EPS (diluted)
- −$4.80
- EBITDA
- $388M
- Operating Income
- $90.1M
Balance Sheet
As of Jun 27, 2026- Cash and cash equivalents
- $192M
- Total Debt
- $2.63B
- Net Debt
- $2.43B
- Total Assets
- $7.53B
- Total Liabilities
- $4.64B
- Shareholders' Equity
- $2.84B
Cash Flow
Trailing 12 months- Operating Cash Flow
- $582M
- Capital Expenditure
- $212M
- Free Cash Flow
- $371M
Dividends and risk
Last 12 months- Dividend Yield
- 0.0%
- Dividend / Share
- $0.00
- Beta (5Y)
- 1.41
Every ratio is calculated from the company’s reported figures.
Note
Revenue is roughly flat year over year at $4.00B.
Watch
Lost $238M over the last 12 months.
Watch
Net debt is 6.3× EBITDA ($2.43B), a heavy load.
Note
Free cash flow of $371M, 9.3% of revenue.
Written by fixed rules from the reported figures, not by a person or an AI.
Latest report
Pro10-K for the fiscal year ended Dec 27, 2025 · filed Feb 18, 2026
The score and findings for the newest report are part of CoreStock Pro, coming soon. Every earlier report is free.
Score of each annual report
0 to 100 · 60 means nothing notable · tap a column for its details
2024 · 10-K33Serious concerns
33Serious concerns
10-K for the fiscal year ended Dec 28, 2024
Filed Feb 19, 2025 · Read the filing on EDGAR
- Revenue slipped 1.9% to $4.05 billion, but operating income fell 63% to $227 million and net income dropped to $10.3 million from $474.6 million.
- A $215 million goodwill write-down hit the Biologics business after it lost key customers in December 2024; lower contract manufacturing revenue is expected in 2025.
- An FDA inspection of a contract manufacturing site brought formal observations, after a client's product application was rejected and its trials put on hold.
- Cash from operations rose to $734.6 million, and debt fell by about $414 million; the monkey-import investigations continue, with civil settlement talks under way.
Business momentum
Sharp deterioration
“In fiscal year 2024, our operating income and operating income margin were $227.3 million and 5.6%, respectively, compared with $617.3 million and 14.9%, respectively, in fiscal year 2023.”
Outlook
Cautious
“continuing to reprioritize pipelines or eliminate some programs, which influences our cautious outlook for the near-term biopharmaceutical demand environment”
Financial stress
Low
“Based on our current business plan, we believe that our existing funds, when combined with cash generated from operations and our access to financing resources, are sufficient to fund our operations for the foreseeable future.”
Tone against the previous report
More negative
Red flags
- Medium
Large write-down
“it was determined that the fair value of the reporting unit was below its carrying value, resulting in a goodwill impairment of approximately $215.0 million”
- Medium
Other
“subsequently the FDA conducted an inspection at the same Company facility resulting in the Company receiving a Form FDA 483 Notice of Inspectional Observations”
- Minor
Investigation
“we recorded a charge of $27 million to costs of products sold within the accompanying consolidated statements of income to reflect the reduction in carrying value of this inventory to zero”
Positives
Operating cash flow rose and debt was paid down
“During fiscal year 2024, our cash flows from operations was $734.6 million compared with $683.9 million for fiscal year 2023.”
Cost cuts expected to deliver sizeable annual savings
“will result in approximately $225 million of cost savings on an annualized basis, of which approximately $100 million impacted fiscal 2024”
Securities class action dismissed, though the plaintiff has appealed
“On July 1, 2024, the court dismissed the complaint, denied the plaintiff’s informal request for leave to amend, and entered judgment for defendants.”
Concerns
Backlog in the largest segment keeps shrinking as clients cut spending
“DSA backlog decreased to $2.0 billion as of December 28, 2024 from $2.5 billion as of December 30, 2023.”
Contract manufacturing revenue expected to fall in 2025
“the Company expects lower revenue from commercial clients to impact its CDMO business in 2025”
Monkey-import investigations remain unresolved with unknown penalties
“The Company cannot predict the timing, outcome or possible impact of the investigations, including without limitation any potential fines, penalties or liabilities.”
New risks since the previous report
Loss of key contract manufacturing customers
“in December 2024, our Biologics business experienced the loss of certain key customers, ultimately resulting in a reduction in its long range financial outlook”
FDA findings at a contract manufacturing site could cost business
“as a result of observations made during pre-license inspections at a Company facility, (1) one biologics license application for a specific therapeutic treatment had received a complete response letter from the FDA”
Possible cuts to government research grants could reduce academic demand
“the NIH announced on February 7, 2025, a policy significantly reducing research grants by limiting payments for indirect overhead”
Possible further goodwill write-down in Discovery Services
“As of the annual impairment test date, the fair value of the reporting unit exceeded its carrying value by approximately 16% and no impairment was recognized as of December 28, 2024.”
Possible international limits on monkey exports from Cambodia
“decided to postpone review of proposed restrictions on the exportation of NHPs from Cambodia until a future CITES meeting, which is expected to occur in late 2025”
Biggest risks named
- Weak drug-industry and biotech spending on early research
- Government investigations and shareholder lawsuits over monkey imports
- Limited monkey supply while Cambodian shipments stay suspended
- Customer losses and FDA quality issues in contract manufacturing
- Further goodwill write-downs in Biologics and Discovery Services
Artificial intelligence in this business: Mentioned
How the score adds up
| Starting point | 60 | |
| Business momentum | −15 | |
| Outlook | −2 | |
| Tone against the previous report | −2 | |
| Financial stress | 0 | |
| Red flags | −6.3 | |
| New risks | −2 | |
| Score | 33 | |
Written by AI (Claude Opus 5.5) from the report’s text. 17 of 17 quotes were found word for word in the filing; the rest are left out. Not investment advice.
All scored reports
| Period | Report | Filed | Score | Momentum | Red flags |
|---|---|---|---|---|---|
| 10-K | Feb 18, 2026 | Pro | |||
| 10-K | Feb 19, 2025 | 33 | Sharp deterioration | 2 medium1 minor | |
| 10-K | Feb 14, 2024 | 43 | Mixed | 2 medium2 minor | |
| 10-K | Feb 22, 2023 | 58 | Improving | 1 medium | |
| 10-K | Feb 16, 2022 | 75 | Strong improvement | None | |
| 10-K | Feb 17, 2021 | 75 | Strong improvement | None | |
| 10-K | Feb 11, 2020 | 66 | Improving | 1 minor | |
| 10-K | Feb 13, 2019 | 76 | Strong improvement | None | |
| 10-K | Feb 13, 2018 | 55 | Mixed | 1 medium1 minor | |
| 10-K | Feb 14, 2017 | 74 | Strong improvement | None |
How these scores work
An AI model reads the management discussion, risk factors and legal sections of each report and records what they say, quoting the filing word for word. Fixed rules then turn those findings into a score from 0 to 100, where 60 means nothing notable either way. A score describes the report, not whether the stock is a good investment, and the AI may know how things turned out later, which can colour older scores. Read the methodology
From the 10-Q for Q2 FY2026 (period ended Jun 27, 2026), filed Aug 5, 2026. View filings on SEC EDGAR